valproic acid has been researched along with Depression in 71 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Ketamine has been shown to rapidly and robustly decrease symptoms of depression in depressed patients with bipolar disorder." | 9.20 | A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. ( Ionescu, DF; Luckenbaugh, DA; Niciu, MJ; Richards, EM; Zarate, CA, 2015) |
| " Patients who did not meet the criteria for a bimodal response after up to 16-weeks of open-label treatment with lithium plus divalproex, as measured by MADRS (Montgomery-Asberg Depression Rating Scale) ≤ 19, YMRS ( Young Mania Rating Scale) ≤ 12 and GAF (Global Assessment of Functioning) = 51 for 4 weeks, were randomized to a 12- week, double-blind addition of lamotrigine or placebo to lithium plus divalproex." | 9.14 | Lamotrigine adjunctive therapy to lithium and divalproex in depressed patients with rapid cycling bipolar disorder and a recent substance use disorder: a 12-week, double-blind, placebo-controlled pilot study. ( Calabrese, JR; Chan, PK; Conroy, C; Fang, Y; Findling, RL; Ganocy, SJ; Gao, K; Kemp, DE; Serrano, MB; Wang, Z, 2010) |
| "These pilot data, from the first prospective comparison study of risperidone and olanzapine in bipolar disorder, suggest that adjunctive administration of either agent may reduce depressive symptom severity." | 9.11 | The antidepressant effects of risperidone and olanzapine in bipolar disorder. ( Kennedy, SH; Konarski, JZ; Mancini, DA; McCann, S; McIntyre, RS; Srinivasan, J, 2004) |
| " Wild-type (WT) mice displayed increased anxiety and depression after chronic administration of VPA for 14 days, when the expression of p35 was decreased." | 5.72 | Valproic Acid-Induced Anxiety and Depression Behaviors are Ameliorated in p39 Cdk5 Activator-Deficient Mice. ( Ando, K; Hisanaga, SI; Kawakami, A; Ohshima, T; Takahashi, M; Takasugi, T; Wei, R, 2022) |
| "Corticosterone plasma level was increased in the CUMS compared to the non-stressed group (p < 0." | 5.56 | Valproic acid administration exerts protective effects against stress-related anhedonia in rats. ( Barati, M; Eslami, M; Goudarzi, M; Mehrabi, S; Nahavandi, A; Shahbazi, A, 2020) |
| " Ketamine has been shown to rapidly and robustly decrease symptoms of depression in depressed patients with bipolar disorder." | 5.20 | A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. ( Ionescu, DF; Luckenbaugh, DA; Niciu, MJ; Richards, EM; Zarate, CA, 2015) |
| "It has been suggested that the anticonvulsant drug pregabalin may be useful in some anxiety disorders." | 5.19 | Effect of pregabalin augmentation in treatment of patients with combat-related chronic posttraumatic stress disorder: a randomized controlled trial. ( Baniasadi, M; Fayyazi Bordbar, MR; Hosseini, G; Mostafavi Toroghi, H; Rezaei Ardani, A, 2014) |
| " Patients who did not meet the criteria for a bimodal response after up to 16-weeks of open-label treatment with lithium plus divalproex, as measured by MADRS (Montgomery-Asberg Depression Rating Scale) ≤ 19, YMRS ( Young Mania Rating Scale) ≤ 12 and GAF (Global Assessment of Functioning) = 51 for 4 weeks, were randomized to a 12- week, double-blind addition of lamotrigine or placebo to lithium plus divalproex." | 5.14 | Lamotrigine adjunctive therapy to lithium and divalproex in depressed patients with rapid cycling bipolar disorder and a recent substance use disorder: a 12-week, double-blind, placebo-controlled pilot study. ( Calabrese, JR; Chan, PK; Conroy, C; Fang, Y; Findling, RL; Ganocy, SJ; Gao, K; Kemp, DE; Serrano, MB; Wang, Z, 2010) |
| "These pilot data, from the first prospective comparison study of risperidone and olanzapine in bipolar disorder, suggest that adjunctive administration of either agent may reduce depressive symptom severity." | 5.11 | The antidepressant effects of risperidone and olanzapine in bipolar disorder. ( Kennedy, SH; Konarski, JZ; Mancini, DA; McCann, S; McIntyre, RS; Srinivasan, J, 2004) |
| " Several treatments [monoamine oxidase inhibitors (MAOIs), ziprasidone, aripiprazole and risperidone] have limited or no therapeutic activity in bipolar depression." | 4.90 | Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis. ( Cornelius, V; Smith, L; Taylor, DM; Young, AH, 2014) |
| "In terms of antidepressant drugs prescribed in hospital admission, during stay and discharge, the number of sertraline and venlafaxine prescriptions were associated with the number of VaD patients whilst the number of mirtazapine prescriptions was associated with frontotemporal dementia patients." | 4.12 | Multi-dimensional relationships among dementia, depression and prescribed drugs in England and Wales hospitals. ( Finn, DP; Joshi, A; McClean, PL; Todd, S; Wong-Lin, K, 2022) |
| "299 patients with uni- and bipolar depression treated with rTMS were selected for analysis in respect to intake of lithium, lamotrigine and valproic acid." | 4.02 | Antidepressant effect of repetitive transcranial magnetic stimulation is not impaired by intake of lithium or antiepileptic drugs. ( Abdelnaim, MA; Deppe, M; Hebel, T; Kreuzer, PM; Langguth, B; Mohonko, A; Poeppl, TB; Rupprecht, R; Schecklmann, M, 2021) |
| " Epilepsy-associated comorbid depression was evaluated by tail suspension test, sucrose preference test, and plasma corticosterone levels, whereas epilepsy-associated memory deficit condition was assessed by step-through paradigm, Morris water maze, and nitrite levels." | 3.96 | Exploring the ameliorative role of α7 neuronal nicotinic acetylcholine receptor modulation in epilepsy and associated comorbidities in post-PTZ-kindled mice. ( Goel, RK; Kaur, S; Sharma, NK, 2020) |
| "Female sex, refractoriness, and clonazepam use may be risk factors for depression after epilepsy diagnosis." | 3.96 | Factors associated with depression in people with epilepsy: a retrospective case-control analysis. ( Chang, RSK; Ho, PH; Leung, IYH; Leung, WCY, 2020) |
| " Owing to the major role of neuronal nitric oxide synthase (nNOS) in brain and ineffectiveness of antiepileptic drugs (AEDs) in restoring nitrosative stress, the present study was envisaged to evaluate the adjuvant nNOS inhibitor, 7-nitroindazole (7-NI) with valproic acid for combined treatment of epilepsy and associated depression." | 3.85 | Adjuvant neuronal nitric oxide synthase inhibition for combined treatment of epilepsy and comorbid depression. ( Goel, RK; Singh, T, 2017) |
| "The present study aimed to develop a neurochemistry-based single or adjuvant therapy approach for comprehensive management of epilepsy and associated depression employing pentylenetetrazole-kindled animals." | 3.83 | Evidence in support of using a neurochemistry approach to identify therapy for both epilepsy and associated depression. ( Goel, RK; Singh, T, 2016) |
| "Valproic acid (VPA), widely used as mood stablizer, has been shown therapeutic effects in controlling both episodes of mania and depression." | 3.77 | Microinjection of valproic acid into the ventrolateral orbital cortex exerts an antidepressant-like effect in the rat forced swim test. ( Chen, T; Dang, Y; Huang, J; Luo, Q; Xing, B; Zhang, H; Zhao, Y, 2011) |
| "Two cases of acute valproic acid poisoning with central nervous system depression and raised ammonia level without hepatotoxicity were reported." | 3.74 | Two cases of valproic acid poisoning treated with L-carnitine. ( Chan, YC; Lau, FL; Tse, ML, 2007) |
| "A 47-year-old white man with a history of bipolar disorder was being maintained on citalopram 40 mg once daily and zolpidem 5 mg at bedtime." | 3.72 | Somnambulism due to probable interaction of valproic acid and zolpidem. ( Bhatia, SC; Petty, F; Ramaswamy, S; Sattar, SP, 2003) |
| "The use of valproate as a treatment for cocaine dependence is not supported." | 2.74 | Valproate treatment and cocaine cue reactivity in cocaine dependent individuals. ( Reid, MS; Thakkar, V, 2009) |
| "The progression in severity of withdrawal symptoms (increase in CIWA-Ar above baseline) was also significantly greater in the placebo group (p < 0." | 2.70 | Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial. ( Baer, JS; Malte, CA; Reoux, JP; Saxon, AJ; Sloan, KL, 2001) |
| "Corticosterone plasma level was increased in the CUMS compared to the non-stressed group (p < 0." | 1.56 | Valproic acid administration exerts protective effects against stress-related anhedonia in rats. ( Barati, M; Eslami, M; Goudarzi, M; Mehrabi, S; Nahavandi, A; Shahbazi, A, 2020) |
| "Valproic acid treatment marginally enhanced global DNA methylation in the frontal cortex." | 1.51 | Brain derived neurotrophic factor expression and DNA methylation in response to subchronic valproic acid and/or aldosterone treatment. ( Balagova, L; Buzgoova, K; Graban, J; Hlavacova, N; Jezova, D, 2019) |
| "The number of seizure-free patients in the last 4 weeks was overall CBZ/VPA/LTG/LEV=60%/79%/67%/67%, for generalized epilepsy was CBZ/VPA/LTG/LEV=67%/89%/65%/94%, and for localization-related epilepsy was CBZ/VPA/LTG/LEV=59%/71%/67%/57%." | 1.46 | Efficacy and tolerability of anti-epileptic drugs-an internet study. ( Baker, G; Wieshmann, UC, 2017) |
| "All patients ≥16years of age with epilepsy for ≥12months were routinely asked to complete the Liverpool Adverse Event Profile (LAEP) just before their appointment." | 1.43 | Specific adverse effects of antiepileptic drugs--A true-to-life monotherapy study. ( Fidzinski, P; Gaus, V; Holtkamp, M; Kowski, AB; Losch, F; Weissinger, F, 2016) |
| "Epilepsy is one of the major neurological disorders frequently associated with psychiatric disorders such as depression." | 1.43 | Adjuvant indoleamine 2,3-dioxygenase enzyme inhibition for comprehensive management of epilepsy and comorbid depression. ( Goel, RK; Singh, T, 2016) |
| " Chronic administration of lithium chloride or valproic acid, two clinically effective mood stabilizers, reverses the majority of these behavioral abnormalities." | 1.42 | Mice heterozygous for cathepsin D deficiency exhibit mania-related behavior and stress-induced depression. ( Duan, S; Han, Y; Li, X; Lou, H; Lu, Y; Zhen, X; Zhou, R; Zhu, L, 2015) |
| "Depression is a common worldwide mental disorder whose etiology remains unclear; there is also a lack of effective therapeutic agents." | 1.42 | Enhancing tyrosine hydroxylase and tryptophan hydroxylase expression and improving oxidative stress involved in the antidepressant effect of sodium valproate on rats undergoing chronic unpredicted stress. ( Hu, XY; Jiang, XH; Liu, D; Qiu, HM; Yang, JX; Zhou, QX, 2015) |
| " As a consequence, if a combination of valproic acid with doxepin or venlafaxine is administered, cautious dosing is advisable and TDM should be performed." | 1.40 | Interaction of valproic acid and the antidepressant drugs doxepin and venlafaxine: analysis of therapeutic drug monitoring data under naturalistic conditions. ( Deckert, J; Hempel, S; Pfuhlmann, B; Proft, F; Reif, A; Riederer, P; Unterecker, S, 2014) |
| "Mixed connective tissue disorder (MCTD) with predominant polymyositis and neuropsychiatric manifestations was diagnosed as the patient had anti-RNP positive with significantly raised muscle enzymes." | 1.40 | Depression and seizures as the main neuropsychiatric manifestation of mixed connective tissue disorder. ( Kiani, IG; Qureshi, SH; Shah, F, 2014) |
| "The patient developed acute renal failure, and also had fever and unilateral ear inflammation." | 1.35 | Acute renal failure following detergent ingestion. ( Lim, YC, 2009) |
| "Risks have been associated with the long-term use of antidepressant in the treatment of bipolar disorder." | 1.31 | Long-term naturalistic treatment of depressive symptoms in bipolar illness with divalproex vs. lithium in the setting of minimal antidepressant use. ( Ghaemi, SN; Goodwin, FK, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (4.23) | 18.7374 |
| 1990's | 7 (9.86) | 18.2507 |
| 2000's | 25 (35.21) | 29.6817 |
| 2010's | 28 (39.44) | 24.3611 |
| 2020's | 8 (11.27) | 2.80 |
| Authors | Studies |
|---|---|
| Xie, T | 1 |
| Li, R | 1 |
| Long, X | 1 |
| Chen, J | 1 |
| Ye, L | 1 |
| Wang, J | 1 |
| Jiang, G | 1 |
| Lv, J | 1 |
| Takahashi, M | 1 |
| Takasugi, T | 1 |
| Kawakami, A | 1 |
| Wei, R | 1 |
| Ando, K | 1 |
| Ohshima, T | 1 |
| Hisanaga, SI | 1 |
| Joshi, A | 1 |
| Todd, S | 1 |
| Finn, DP | 1 |
| McClean, PL | 1 |
| Wong-Lin, K | 1 |
| Sharma, NK | 1 |
| Kaur, S | 1 |
| Goel, RK | 4 |
| Goudarzi, M | 1 |
| Nahavandi, A | 1 |
| Mehrabi, S | 1 |
| Eslami, M | 1 |
| Shahbazi, A | 1 |
| Barati, M | 1 |
| Ozkul, Y | 1 |
| Taheri, S | 1 |
| Bayram, KK | 1 |
| Sener, EF | 1 |
| Mehmetbeyoglu, E | 1 |
| Öztop, DB | 1 |
| Aybuga, F | 1 |
| Tufan, E | 1 |
| Bayram, A | 1 |
| Dolu, N | 1 |
| Zararsiz, G | 1 |
| Kianmehr, L | 1 |
| Beyaz, F | 1 |
| Doganyigit, Z | 1 |
| Cuzin, F | 1 |
| Rassoulzadegan, M | 1 |
| Ho, PH | 1 |
| Leung, WCY | 1 |
| Leung, IYH | 1 |
| Chang, RSK | 1 |
| Hebel, T | 1 |
| Abdelnaim, MA | 1 |
| Deppe, M | 1 |
| Kreuzer, PM | 1 |
| Mohonko, A | 1 |
| Poeppl, TB | 1 |
| Rupprecht, R | 1 |
| Langguth, B | 1 |
| Schecklmann, M | 1 |
| Lima, IVA | 1 |
| Almeida-Santos, AF | 1 |
| Ferreira-Vieira, TH | 1 |
| Aguiar, DC | 1 |
| Ribeiro, FM | 1 |
| Campos, AC | 1 |
| de Oliveira, ACP | 1 |
| Silva, EF | 1 |
| Silva, AI | 1 |
| Asth, L | 1 |
| Souza, LS | 1 |
| Zaveri, NT | 1 |
| Guerrini, R | 1 |
| Calo', G | 1 |
| Ruzza, C | 1 |
| Gavioli, EC | 1 |
| Buzgoova, K | 1 |
| Graban, J | 1 |
| Balagova, L | 1 |
| Hlavacova, N | 1 |
| Jezova, D | 1 |
| Jin, Q | 1 |
| Fu, Z | 1 |
| Guan, L | 1 |
| Jiang, H | 1 |
| Unterecker, S | 1 |
| Reif, A | 1 |
| Hempel, S | 1 |
| Proft, F | 1 |
| Riederer, P | 1 |
| Deckert, J | 1 |
| Pfuhlmann, B | 1 |
| Liu, D | 2 |
| Qiu, HM | 2 |
| Fei, HZ | 1 |
| Hu, XY | 2 |
| Xia, HJ | 1 |
| Wang, LJ | 1 |
| Qin, LJ | 1 |
| Jiang, XH | 2 |
| Zhou, QX | 2 |
| Powell, TR | 1 |
| Powell-Smith, G | 1 |
| Haddley, K | 1 |
| Mcguffin, P | 1 |
| Quinn, J | 1 |
| Schalkwyk, LC | 1 |
| Farmer, AE | 1 |
| D'Souza, UM | 1 |
| Kiani, IG | 1 |
| Qureshi, SH | 1 |
| Shah, F | 1 |
| Tunca, Z | 1 |
| Ozerdem, A | 1 |
| Ceylan, D | 1 |
| Yalçın, Y | 1 |
| Can, G | 1 |
| Resmi, H | 1 |
| Akan, P | 1 |
| Ergör, G | 1 |
| Aydemir, O | 1 |
| Cengisiz, C | 1 |
| Kerim, D | 1 |
| Taylor, DM | 1 |
| Cornelius, V | 1 |
| Smith, L | 1 |
| Young, AH | 1 |
| Ionescu, DF | 1 |
| Luckenbaugh, DA | 2 |
| Niciu, MJ | 1 |
| Richards, EM | 1 |
| Zarate, CA | 2 |
| Baniasadi, M | 1 |
| Hosseini, G | 1 |
| Fayyazi Bordbar, MR | 1 |
| Rezaei Ardani, A | 1 |
| Mostafavi Toroghi, H | 1 |
| Zhou, R | 1 |
| Lu, Y | 1 |
| Han, Y | 1 |
| Li, X | 1 |
| Lou, H | 1 |
| Zhu, L | 1 |
| Zhen, X | 1 |
| Duan, S | 1 |
| Yang, JX | 1 |
| Salpekar, JA | 1 |
| Joshi, PT | 1 |
| Axelson, DA | 1 |
| Reinblatt, SP | 1 |
| Yenokyan, G | 1 |
| Sanyal, A | 1 |
| Walkup, JT | 1 |
| Vitiello, B | 1 |
| Luby, JL | 1 |
| Wagner, KD | 1 |
| Nusrat, N | 1 |
| Riddle, MA | 1 |
| Wang, CY | 1 |
| Cheng, CW | 1 |
| Wang, WH | 1 |
| Chen, PS | 2 |
| Tzeng, SF | 1 |
| Kowski, AB | 1 |
| Weissinger, F | 1 |
| Gaus, V | 1 |
| Fidzinski, P | 1 |
| Losch, F | 1 |
| Holtkamp, M | 1 |
| Su, CL | 1 |
| Su, CW | 1 |
| Hsiao, YH | 1 |
| Gean, PW | 1 |
| Singh, T | 3 |
| Wu, HF | 1 |
| Chen, YJ | 1 |
| Lee, CW | 1 |
| Chen, IT | 1 |
| Lin, HC | 1 |
| Wieshmann, UC | 1 |
| Baker, G | 1 |
| Lambru, G | 1 |
| Castellini, P | 1 |
| Bini, A | 1 |
| Evangelista, A | 1 |
| Manzoni, GC | 1 |
| Torelli, P | 1 |
| Arora, M | 1 |
| Praharaj, SK | 1 |
| Sinha, VK | 1 |
| Sarkar, S | 1 |
| Reid, MS | 1 |
| Thakkar, V | 1 |
| Lim, YC | 1 |
| Barbier, E | 1 |
| Wang, JB | 1 |
| Wang, Z | 1 |
| Gao, K | 1 |
| Kemp, DE | 1 |
| Chan, PK | 1 |
| Serrano, MB | 1 |
| Conroy, C | 1 |
| Fang, Y | 1 |
| Ganocy, SJ | 1 |
| Findling, RL | 1 |
| Calabrese, JR | 3 |
| Xing, B | 1 |
| Zhao, Y | 1 |
| Zhang, H | 1 |
| Dang, Y | 1 |
| Chen, T | 1 |
| Huang, J | 1 |
| Luo, Q | 1 |
| Kobayashi, H | 1 |
| Iwata, M | 1 |
| Mitani, H | 1 |
| Yamada, T | 1 |
| Nakagome, K | 1 |
| Kaneko, K | 1 |
| Kamalinia, G | 1 |
| Brand, S | 1 |
| Ghaeli, P | 1 |
| Abedi, N | 1 |
| Bajoghli, H | 1 |
| Sharifi, V | 1 |
| Zahiroddin, A | 1 |
| Amini, M | 1 |
| Rouini, MR | 1 |
| Holsboer-Trachsler, E | 1 |
| Mohammadpoor, AH | 1 |
| Krępuła, K | 1 |
| Bidzińska-Speichert, B | 1 |
| Lenarcik, A | 1 |
| Tworowska-Bardzińska, U | 1 |
| Sattar, SP | 1 |
| Ramaswamy, S | 1 |
| Bhatia, SC | 1 |
| Petty, F | 1 |
| Neumann, NU | 1 |
| Bretschneider, S | 1 |
| Bullacher, Ch | 1 |
| Frasch, K | 1 |
| Hess, R | 1 |
| Wittek, R | 1 |
| Pekary, AE | 1 |
| Sattin, A | 1 |
| Meyerhoff, JL | 1 |
| Chilingar, M | 1 |
| McIntyre, RS | 1 |
| Mancini, DA | 1 |
| Srinivasan, J | 1 |
| McCann, S | 1 |
| Konarski, JZ | 1 |
| Kennedy, SH | 1 |
| Uthamalingam, S | 1 |
| Kumar, S | 1 |
| Vasudevan, AR | 1 |
| Winters, WG | 1 |
| Dunner, DL | 1 |
| Debattista, C | 1 |
| Solomon, A | 1 |
| Arnow, B | 1 |
| Kendrick, E | 1 |
| Tilston, J | 1 |
| Schatzberg, AF | 1 |
| Kratochvil, CJ | 1 |
| Varley, C | 1 |
| Cummins, TK | 1 |
| Martin, A | 1 |
| Patel, NC | 1 |
| DelBello, MP | 1 |
| Kowatch, RA | 1 |
| Strakowski, SM | 1 |
| Mah, L | 1 |
| Singh, J | 1 |
| Duan, YF | 1 |
| Manji, HK | 1 |
| Drevets, WC | 1 |
| Muzina, DJ | 1 |
| Colangelo, E | 1 |
| Manning, JS | 1 |
| Grunze, H | 1 |
| Adli, M | 1 |
| Bauer, M | 1 |
| Berger, M | 1 |
| Bergmann, A | 1 |
| Bräunig, P | 1 |
| Bschor, T | 1 |
| Falkai, P | 1 |
| Gastpar, M | 1 |
| Greil, W | 1 |
| Kasper, S | 1 |
| Krüger, S | 1 |
| Laux, G | 1 |
| Müller, WE | 1 |
| Naber, D | 1 |
| Walden, J | 1 |
| Macphee, GJ | 1 |
| Stewart, DA | 1 |
| Ferrero, AJ | 1 |
| Cereseto, M | 1 |
| Sifonios, LL | 1 |
| Reinés, A | 1 |
| Peixoto, E | 1 |
| Rubio, MC | 1 |
| Wikinski, S | 1 |
| Arnold, G | 1 |
| Schuh-Hofer, S | 1 |
| Chan, YC | 1 |
| Tse, ML | 1 |
| Lau, FL | 1 |
| Wolf, P | 1 |
| Inoue, Y | 1 |
| Röder-Wanner, UU | 1 |
| Tsai, JJ | 1 |
| Horne, M | 1 |
| Lindley, SE | 1 |
| Ford, N | 1 |
| Blumer, D | 1 |
| Herzog, AG | 1 |
| Himmelhoch, J | 1 |
| Salgueiro, CA | 1 |
| Ling, FW | 1 |
| Lapierre, O | 1 |
| Dubreucq, JL | 1 |
| Beauchemin, MA | 1 |
| Vinet, B | 1 |
| Putnam, GP | 1 |
| O'Quinn, S | 1 |
| Bolden-Watson, CP | 1 |
| Davis, RL | 1 |
| Gutterman, DL | 1 |
| Fox, AW | 1 |
| Swann, AC | 1 |
| Bowden, CL | 1 |
| Dilsaver, SC | 1 |
| Morris, DD | 1 |
| Ghaemi, SN | 1 |
| Goodwin, FK | 1 |
| Reoux, JP | 1 |
| Saxon, AJ | 1 |
| Malte, CA | 1 |
| Baer, JS | 1 |
| Sloan, KL | 1 |
| Lander, CM | 1 |
| Donnan, GA | 1 |
| Bladin, PF | 1 |
| Vajda, FJ | 1 |
| Post, RM | 2 |
| Altshuler, LL | 2 |
| Ketter, TA | 1 |
| Denicoff, K | 1 |
| Weiss, SR | 1 |
| Devinsky, O | 1 |
| Theodore, W | 1 |
| Vinar, O | 1 |
| Dvorák, A | 1 |
| Obrovská, V | 1 |
| Krisková, M | 1 |
| Turcek, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Investigation of the Rapid (Next Day) Antidepressant Effects of an NMDA Antagonist[NCT00088699] | Phase 1/Phase 2 | 67 participants (Actual) | Interventional | 2004-07-26 | Completed | ||
| Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD[NCT02884908] | Phase 3 | 252 participants (Anticipated) | Interventional | 2016-09-30 | Active, not recruiting | ||
| Treatment of Early Age Mania (TEAM) Study[NCT00057681] | Phase 3 | 379 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| Prophylactic Use of Immediate Postpartum Sertraline to Prevent Postpartum Depression: A Double Blind Randomized Placebo Controlled Trial[NCT02235064] | 2 participants (Actual) | Interventional | 2014-07-31 | Terminated (stopped due to Low recruitment, completion of funding cycle) | |||
| Placebo Controlled Trial of Depakote ER in Alcohol Dependent Patients With Mood and/or Anxiety Symptoms[NCT00202514] | Phase 2/Phase 3 | 40 participants | Interventional | 2004-09-30 | Completed | ||
| Prospective Assessment of Valproate on Ethanol Withdrawal[NCT03235531] | Phase 4 | 210 participants (Anticipated) | Interventional | 2017-07-11 | Recruiting | ||
| Monitoring of Seizures, EEG and Serum Antiepileptic Drug Concentrations in Patients With Uncontrolled Epilepsy[NCT00001149] | 900 participants | Observational | 1975-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Antidepressant effects were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). It is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. (NCT00088699)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine - Healthy Volunteers | 1.17 |
| Placebo - Healthy Volunteers | 1.48 |
| Ketamine - MDD Patients | 33.83 |
| Placebo - MDD Patients | 31.82 |
Antidepressant effects were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). It is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. (NCT00088699)
Timeframe: Day 1
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine - Healthy Volunteers | 2.45 |
| Placebo - Healthy Volunteers | 0.67 |
| Ketamine - MDD Patients | 23.73 |
| Placebo - MDD Patients | 30.68 |
The Clinical Global Impressions-Bipolar (CGI-BP) assessment instrument measured improvement in mania, depression, and overall bipolar illness. The primary outcome measure was mania improvement, which measured the change in mania from baseline. Scores were 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. (NCT00057681)
Timeframe: Measured at Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Randomized Medication - Lithium | 2.49 |
| Randomized Medication - Divalproex Sodium | 2.73 |
| Randomized Medication - Risperidone | 1.70 |
The K-SADS Mania Rating Scale (KMRS) is comprised of 15 items modified from WASH-U-KSADS items. The individual items are scored on a 1-6 severity scale and then these item scores are summed to create an overall KMRS score. Guidelines for interpretation are as follows: 0-11 = no or minimal mania, 12-17 = mild mania, 18-25 = moderate mania, 26+ = marked or worse mania. The maximum possible score is 64. (NCT00057681)
Timeframe: Measured at Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Randomized Medication - Lithium | 24.06 |
| Randomized Medication - Divalproex Sodium | 26.31 |
| Randomized Medication - Risperidone | 14.58 |
The Modified Side Effects Form for Children and Adolescents includes 62 potential side effects, with measures of frequency and severity for each item. Frequencies are 0=not present, 1=1-2 days, 2=3-4 days, 3=5-7 days. Severity scores are 0=not present, 1=mild (does not interfere with functioning), 2=moderate (some interference with functioning), 3=severe (functioning is significantly impaired because of side effects). Items for cardiovascular, gastrointestinal, central nervous system, ocular, mouth and nose, genito urinary, dermatology, musculo-skeletal, and other side effects are included. For analyses, side effects that were reported at any frequency and a severity of 2 or greater were considered present. (NCT00057681)
Timeframe: Measured at Week 8
| Intervention | side effects at week 8 (Mean) |
|---|---|
| Randomized Medication - Lithium | 5.11 |
| Randomized Medication - Divalproex Sodium | 4.95 |
| Randomized Medication - Risperidone | 3.70 |
The Antidepressant Side-Effect Checklist (ASEC) was employed to detect any adverse reaction to treatment regimens (NCT02235064)
Timeframe: Discharge from hospital to 12 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 1 |
"Patients met with single psychiatrist (co-investigator), blinded to group assignment, who evaluated the patient using Edinburgh Postpartum Depression Screen, Hamilton Depression Rating Scale, Global Assessment of Functioning Scale, and clinical assessment~0 = No postpartum depression up to 12 weeks following discharge from hospital~1 = Postpartum depression up to 12 weeks following discharge from hospital" (NCT02235064)
Timeframe: Discharge from hospital to 12 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 12 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 4 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 8 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 12 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 4 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 8 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 12 weeks postpartum
| Intervention | Grams (Mean) |
|---|---|
| Sertraline | 5301 |
| Placebo | 4734 |
(NCT02235064)
Timeframe: 4 weeks postpartum
| Intervention | Grams (Mean) |
|---|---|
| Sertraline | 3033 |
| Placebo | 2750 |
(NCT02235064)
Timeframe: 8 weeks postpartum
| Intervention | Grams (Mean) |
|---|---|
| Sertraline | 5301 |
| Placebo | 3685 |
8 reviews available for valproic acid and Depression
| Article | Year |
|---|---|
Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; | 2014 |
Psychiatric disorders related to polycystic ovary syndrome.
Topics: Antimanic Agents; Bipolar Disorder; Depression; Feeding and Eating Disorders; Female; Hirsutism; Hor | 2012 |
[Persisting deficits after severe depression].
Topics: Adult; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Carbamazepine; Cognition Disor | 2003 |
Differentiating bipolar disorder from depression in primary care.
Topics: Bipolar Disorder; Depression; Depressive Disorder, Major; Diagnosis, Differential; Humans; Lamotrigi | 2007 |
[Clinical standing of valproate treatment of bipolar disorders].
Topics: Acute Disease; Antimanic Agents; Bipolar Disorder; Depression; Drug Therapy, Combination; Humans; Lo | 2007 |
[Comorbidities in migraine patients].
Topics: Adult; Amitriptyline; Analgesics, Non-Narcotic; Anticonvulsants; Anxiety Disorders; Carotid Artery, | 2007 |
ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Bipolar Disorder; Breast Feed | 2008 |
Antiepileptic drugs in affective illness. Clinical and theoretical implications.
Topics: Acute Disease; Anticonvulsants; Benzodiazepines; Bipolar Disorder; Carbamazepine; Depression; Drug T | 1991 |
9 trials available for valproic acid and Depression
| Article | Year |
|---|---|
A single infusion of ketamine improves depression scores in patients with anxious bipolar depression.
Topics: Adult; Affect; Anxiety; Anxiety Disorders; Bipolar Disorder; Cross-Over Studies; Depression; Double- | 2015 |
Effect of pregabalin augmentation in treatment of patients with combat-related chronic posttraumatic stress disorder: a randomized controlled trial.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Anxiety; Combat Disorders; Depression; Double-Blind M | 2014 |
Depression and Suicidality Outcomes in the Treatment of Early Age Mania Study.
Topics: Adolescent; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Child; Depression; Female; Hum | 2015 |
Valproate treatment and cocaine cue reactivity in cocaine dependent individuals.
Topics: Adult; Affect; Antimanic Agents; Cocaine-Related Disorders; Crack Cocaine; Cross-Over Studies; Cues; | 2009 |
Lamotrigine adjunctive therapy to lithium and divalproex in depressed patients with rapid cycling bipolar disorder and a recent substance use disorder: a 12-week, double-blind, placebo-controlled pilot study.
Topics: Adult; Analysis of Variance; Antimanic Agents; Bipolar Disorder; Chi-Square Distribution; Depression | 2010 |
The antidepressant effects of risperidone and olanzapine in bipolar disorder.
Topics: Adolescent; Adult; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Body W | 2004 |
The efficacy of divalproex sodium in the treatment of agitation associated with major depression.
Topics: Adult; Aged; Antimanic Agents; Anxiety; Depression; Depressive Disorder, Major; Female; Humans; Male | 2005 |
Mania: differential effects of previous depressive and manic episodes on response to treatment.
Topics: Antimanic Agents; Bipolar Disorder; Depression; Double-Blind Method; Drug Tolerance; Female; Humans; | 2000 |
Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial.
Topics: Adolescent; Adult; Aged; Alcoholism; Anticonvulsants; Anxiety; Depression; Double-Blind Method; Etha | 2001 |
Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial.
Topics: Adolescent; Adult; Aged; Alcoholism; Anticonvulsants; Anxiety; Depression; Double-Blind Method; Etha | 2001 |
Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial.
Topics: Adolescent; Adult; Aged; Alcoholism; Anticonvulsants; Anxiety; Depression; Double-Blind Method; Etha | 2001 |
Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial.
Topics: Adolescent; Adult; Aged; Alcoholism; Anticonvulsants; Anxiety; Depression; Double-Blind Method; Etha | 2001 |
54 other studies available for valproic acid and Depression
| Article | Year |
|---|---|
Magnetic resonance imaging features of hippocampus and mechanism of neurocognitive dysfunction for antiepileptic drugs in treatment of depression rats.
Topics: Animals; Anticonvulsants; Aspartic Acid; Creatine; Depression; Hippocampus; Magnetic Resonance Imagi | 2022 |
Valproic Acid-Induced Anxiety and Depression Behaviors are Ameliorated in p39 Cdk5 Activator-Deficient Mice.
Topics: Animals; Anticonvulsants; Antimanic Agents; Anxiety; Cytoskeletal Proteins; Depression; Lipid-Linked | 2022 |
Multi-dimensional relationships among dementia, depression and prescribed drugs in England and Wales hospitals.
Topics: Aged; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Depression; Donepezil; Dothiepin | 2022 |
Exploring the ameliorative role of α7 neuronal nicotinic acetylcholine receptor modulation in epilepsy and associated comorbidities in post-PTZ-kindled mice.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Anticonvulsants; Corticosterone; Depression; Dose- | 2020 |
Valproic acid administration exerts protective effects against stress-related anhedonia in rats.
Topics: Anhedonia; Animals; Behavior, Animal; Corticosterone; Depression; Disease Models, Animal; Histone De | 2020 |
A heritable profile of six miRNAs in autistic patients and mouse models.
Topics: Adolescent; Adult; Animals; Anxiety; Autism Spectrum Disorder; Autistic Disorder; Child; Child, Pres | 2020 |
Factors associated with depression in people with epilepsy: a retrospective case-control analysis.
Topics: Adult; Anticonvulsants; Case-Control Studies; Clonazepam; Depression; Epilepsy; Female; Humans; Male | 2020 |
Antidepressant effect of repetitive transcranial magnetic stimulation is not impaired by intake of lithium or antiepileptic drugs.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Depression; Humans; Lamotrigine; Lithi | 2021 |
Antidepressant-like effect of valproic acid-Possible involvement of PI3K/Akt/mTOR pathway.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Dose-Response Relationship, Drug | 2017 |
Nociceptin/orphanin FQ receptor agonists increase aggressiveness in the mouse resident-intruder test.
Topics: Aggression; Agonistic Behavior; Animals; Anxiety; Bipolar Disorder; Carbamazepine; Cycloheptanes; De | 2019 |
Brain derived neurotrophic factor expression and DNA methylation in response to subchronic valproic acid and/or aldosterone treatment.
Topics: Aldosterone; Animals; Brain; Brain-Derived Neurotrophic Factor; Cerebral Cortex; Depression; Disease | 2019 |
Syntheses of Benzo[
Topics: Animals; Antarctic Regions; Anticonvulsants; Antidepressive Agents; Aquatic Organisms; Benzothiazole | 2019 |
Interaction of valproic acid and the antidepressant drugs doxepin and venlafaxine: analysis of therapeutic drug monitoring data under naturalistic conditions.
Topics: Adult; Aged; Antidepressive Agents; Biotransformation; Cyclohexanols; Depression; Dose-Response Rela | 2014 |
Histone acetylation and expression of mono-aminergic transmitters synthetases involved in CUS-induced depressive rats.
Topics: Acetylation; Animals; Anxiety; Depression; Disease Models, Animal; Epigenesis, Genetic; Gene Express | 2014 |
Mood-stabilizers differentially affect housekeeping gene expression in human cells.
Topics: Aged; Antimanic Agents; Cell Line, Transformed; Depression; Dose-Response Relationship, Drug; Female | 2014 |
Depression and seizures as the main neuropsychiatric manifestation of mixed connective tissue disorder.
Topics: Adult; Antibodies, Antinuclear; Anticonvulsants; Antidepressive Agents, Second-Generation; Azathiopr | 2014 |
Alterations in BDNF (brain derived neurotrophic factor) and GDNF (glial cell line-derived neurotrophic factor) serum levels in bipolar disorder: The role of lithium.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Brain-Derived Neurotrophic Factor; Depression; Enzyme-Lin | 2014 |
Mice heterozygous for cathepsin D deficiency exhibit mania-related behavior and stress-induced depression.
Topics: Adaptation, Ocular; Animals; Antidepressive Agents; Bipolar Disorder; Cathepsin D; Corticosterone; D | 2015 |
Enhancing tyrosine hydroxylase and tryptophan hydroxylase expression and improving oxidative stress involved in the antidepressant effect of sodium valproate on rats undergoing chronic unpredicted stress.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Catalase; Depression; Male; Malondialdehyde; Oxida | 2015 |
Postnatal Stress Induced by Injection with Valproate Leads to Developing Emotional Disorders Along with Molecular and Cellular Changes in the Hippocampus and Amygdala.
Topics: Amygdala; Animals; Anxiety; Astrocytes; Cell Count; Cell Differentiation; Cell Proliferation; Cell S | 2016 |
Specific adverse effects of antiepileptic drugs--A true-to-life monotherapy study.
Topics: Adult; Aged; Anticonvulsants; Anxiety; Carbamazepine; Depression; Drug-Related Side Effects and Adve | 2016 |
Epigenetic regulation of BDNF in the learned helplessness-induced animal model of depression.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Butyric Acid; Depression; Disease | 2016 |
Adjuvant indoleamine 2,3-dioxygenase enzyme inhibition for comprehensive management of epilepsy and comorbid depression.
Topics: Animals; Comorbidity; Corticosterone; Depression; Drug Interactions; Enzyme Inhibitors; Epilepsy; Hi | 2016 |
Evidence in support of using a neurochemistry approach to identify therapy for both epilepsy and associated depression.
Topics: Animals; Anticonvulsants; Brain; Depression; Depressive Disorder; Disease Models, Animal; Dopamine; | 2016 |
Alleviation of N-Methyl-D-Aspartate Receptor-Dependent Long-Term Depression via Regulation of the Glycogen Synthase Kinase-3β Pathway in the Amygdala of a Valproic Acid-Induced Animal Model of Autism.
Topics: Animals; Autistic Disorder; Depression; Disease Models, Animal; Enzyme Inhibitors; Glycogen Synthase | 2017 |
Efficacy and tolerability of anti-epileptic drugs-an internet study.
Topics: Adult; Anticonvulsants; Carbamazepine; Depression; Epilepsy; Female; Humans; Internet; Lamotrigine; | 2017 |
Adjuvant neuronal nitric oxide synthase inhibition for combined treatment of epilepsy and comorbid depression.
Topics: Animals; Anticonvulsants; Chemotherapy, Adjuvant; Depression; Dose-Response Relationship, Drug; Enzy | 2017 |
Hemicrania continua evolving from cluster headache responsive to valproic acid.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Depression; Dyspepsia; Female; GABA Agents; Gastritis; Head | 2008 |
Schizencephaly associated with bipolar II disorder.
Topics: Bipolar Disorder; Brain; Citalopram; Depression; Diagnosis, Differential; Dibenzothiazepines; Humans | 2009 |
Acute renal failure following detergent ingestion.
Topics: Acetaminophen; Acute Kidney Injury; Adult; Depression; Detergents; Eating; Female; Fluoxetine; Human | 2009 |
Anti-depressant and anxiolytic like behaviors in PKCI/HINT1 knockout mice associated with elevated plasma corticosterone level.
Topics: Analysis of Variance; Animals; Anxiety; Avoidance Learning; Behavior, Animal; Corticosterone; Cues; | 2009 |
Microinjection of valproic acid into the ventrolateral orbital cortex exerts an antidepressant-like effect in the rat forced swim test.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Dose-Response Relationship, Drug | 2011 |
Valproic acid improves the tolerance for the stress in learned helplessness rats.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Disease Models, Anima | 2012 |
Serum levels of sodium valproate in patients suffering from bipolar disorders: comparing acute and maintenance phases of mania.
Topics: Adult; Bipolar Disorder; Depression; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Sc | 2013 |
Somnambulism due to probable interaction of valproic acid and zolpidem.
Topics: Bipolar Disorder; Citalopram; Depression; Drug Interactions; Drug Therapy, Combination; Humans; Male | 2003 |
Valproate modulates TRH receptor, TRH and TRH-like peptide levels in rat brain.
Topics: Animals; Antimanic Agents; Brain; Brain Chemistry; Depression; Male; Oligopeptides; Rats; Rats, Wist | 2004 |
Drowsiness and disorientation in a woman with depression.
Topics: Antimanic Agents; Confusion; Depression; Female; Humans; Middle Aged; Sleep Stages; Valproic Acid | 2005 |
Interactive case conference. First episode: depression and panic disorder.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Citalopram; Clonazepam; Depression; | 2005 |
Less is more: inpatient management of a child with complex pharmacotherapy.
Topics: Aggression; Amphetamines; Attention Deficit Disorder with Hyperactivity; Child; Clonidine; Depressio | 2006 |
Preliminary study of relationships among measures of depressive symptoms in adolescents with bipolar disorder.
Topics: Adolescent; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Clinica | 2006 |
Regional cerebral glucose metabolic abnormalities in bipolar II depression.
Topics: Amygdala; Antimanic Agents; Bipolar Disorder; Blood Glucose; Brain; Brain Mapping; Depression; Femal | 2007 |
Diagnosis of Parkinsonism in older patients receiving sodium valproate.
Topics: Aged; Depression; Female; Humans; Parkinsonian Disorders; Seizures; Valproic Acid | 2007 |
Cytoskeleton of hippocampal neurons as a target for valproic acid in an experimental model of depression.
Topics: Animals; Antidepressive Agents; Atrophy; Behavior, Animal; Cytoskeleton; Depression; Hippocampus; Im | 2007 |
Two cases of valproic acid poisoning treated with L-carnitine.
Topics: Adolescent; Adult; Anticonvulsants; Antidotes; Carnitine; Depression; Drug Overdose; Female; Humans; | 2007 |
Psychiatric complications of absence therapy and their relation to alteration of sleep.
Topics: Delusions; Depression; Epilepsy, Absence; Ethosuximide; Female; Humans; Hypochondriasis; Hysteria; M | 1984 |
Divalproex sodium in the treatment of aggressive behavior and dysphoria in patients with organic brain syndromes.
Topics: Adult; Aged; Aged, 80 and over; Aggression; Anger; Depression; Humans; Middle Aged; Neurocognitive D | 1995 |
The use of anticonvulsants in posttraumatic stress disorder: case study and overview.
Topics: Adult; Anticonvulsants; Carbamazepine; Depression; Humans; Male; Reflex, Startle; Stress Disorders, | 1996 |
To what extent do premenstrual and interictal dysphoric disorder overlap? Significance for therapy.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepress | 1998 |
Valproic acid intoxication in a patient with bipolar disorder and chronic uremia.
Topics: Antimanic Agents; Bipolar Disorder; Depression; Female; Humans; Hypokinesia; Kidney Failure, Chronic | 1999 |
Migraine polypharmacy and the tolerability of sumatriptan: a large-scale, prospective study.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Anti-As | 1999 |
Long-term naturalistic treatment of depressive symptoms in bipolar illness with divalproex vs. lithium in the setting of minimal antidepressant use.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Depression; Drug Therapy, Combinat | 2001 |
Some aspects of the clinical use of clonazepam in refractory epilepsy.
Topics: Adolescent; Adult; Ataxia; Benzodiazepinones; Child; Clonazepam; Depression; Drug Therapy, Combinati | 1979 |
Depression, anxiety, and temporal lobe epilepsy. Laterality of focus and symptoms.
Topics: Adult; Analysis of Variance; Anxiety; Carbamazepine; Depression; Epilepsy, Temporal Lobe; Female; Fu | 1990 |
Does sodium valproate increase clinical effects of antidepressants?
Topics: Antidepressive Agents; Depression; Double-Blind Method; Drug Interactions; Humans; Valproic Acid | 1989 |